Cargando…
Lactobacillus GG as an Immune Adjuvant for Live Attenuated Influenza Vaccine in Healthy Adults: A Randomized Double Blind Placebo Controlled Trial
BACKGROUND/OBJECTIVES: Live attenuated influenza vaccine (LAIV) protects against influenza by mucosal activation of the immune system. Studies in animals and adults have demonstrated that probiotics improve the immune response to mucosally delivered vaccines. We hypothesized that Lactobacillus GG (L...
Autores principales: | , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071884/ https://www.ncbi.nlm.nih.gov/pubmed/21285968 http://dx.doi.org/10.1038/ejcn.2010.289 |
_version_ | 1782201485041336320 |
---|---|
author | Davidson, Lisa E Fiorino, Anne-Maria Snydman, David R Hibberd, Patricia L |
author_facet | Davidson, Lisa E Fiorino, Anne-Maria Snydman, David R Hibberd, Patricia L |
author_sort | Davidson, Lisa E |
collection | PubMed |
description | BACKGROUND/OBJECTIVES: Live attenuated influenza vaccine (LAIV) protects against influenza by mucosal activation of the immune system. Studies in animals and adults have demonstrated that probiotics improve the immune response to mucosally delivered vaccines. We hypothesized that Lactobacillus GG (LGG) would act as an immune adjuvant to increase rates of seroconversion after LAIV administration. SUBJECTS/METHODS: We conducted a randomized double-blind placebo-controlled pilot study to determine if LGG improved rates of seroconversion after administration of LAIV. We studied 42 healthy adults during the 2007–8 influenza season. All subjects received LAIV and then were randomized to LGG or placebo twice daily for 28 days. HAI titers were assessed at baseline, day 28, and day 56 to determine rates of seroconversion. Subjects were assessed for adverse events throughout the study period. RESULTS: 39 subjects completed the per protocol analysis. Both LGG and LAIV were well tolerated. Protection rates against the vaccine H1N1 and B strains was similar suboptimal in subjects receiving LGG and placebo. For the H3N2 strain, 84% receiving LGG vs. 55% receiving placebo had a protective titer 28 days after vaccination (odds of having a protective titer was 1.84 95% CI 1.04–3.22, P=0.048). CONCLUSION: Lactobacillus GG is potential as an important adjuvant to improve influenza vaccine immunogenicity. Future studies of probiotics as immune adjuvants may need to consider specifically examining vaccine naïve or seronegative subjects, target mucosal immune responses, or focus on groups known to have poor response to influenza vaccines. |
format | Text |
id | pubmed-3071884 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
record_format | MEDLINE/PubMed |
spelling | pubmed-30718842011-10-01 Lactobacillus GG as an Immune Adjuvant for Live Attenuated Influenza Vaccine in Healthy Adults: A Randomized Double Blind Placebo Controlled Trial Davidson, Lisa E Fiorino, Anne-Maria Snydman, David R Hibberd, Patricia L Eur J Clin Nutr Article BACKGROUND/OBJECTIVES: Live attenuated influenza vaccine (LAIV) protects against influenza by mucosal activation of the immune system. Studies in animals and adults have demonstrated that probiotics improve the immune response to mucosally delivered vaccines. We hypothesized that Lactobacillus GG (LGG) would act as an immune adjuvant to increase rates of seroconversion after LAIV administration. SUBJECTS/METHODS: We conducted a randomized double-blind placebo-controlled pilot study to determine if LGG improved rates of seroconversion after administration of LAIV. We studied 42 healthy adults during the 2007–8 influenza season. All subjects received LAIV and then were randomized to LGG or placebo twice daily for 28 days. HAI titers were assessed at baseline, day 28, and day 56 to determine rates of seroconversion. Subjects were assessed for adverse events throughout the study period. RESULTS: 39 subjects completed the per protocol analysis. Both LGG and LAIV were well tolerated. Protection rates against the vaccine H1N1 and B strains was similar suboptimal in subjects receiving LGG and placebo. For the H3N2 strain, 84% receiving LGG vs. 55% receiving placebo had a protective titer 28 days after vaccination (odds of having a protective titer was 1.84 95% CI 1.04–3.22, P=0.048). CONCLUSION: Lactobacillus GG is potential as an important adjuvant to improve influenza vaccine immunogenicity. Future studies of probiotics as immune adjuvants may need to consider specifically examining vaccine naïve or seronegative subjects, target mucosal immune responses, or focus on groups known to have poor response to influenza vaccines. 2011-02-02 2011-04 /pmc/articles/PMC3071884/ /pubmed/21285968 http://dx.doi.org/10.1038/ejcn.2010.289 Text en Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms |
spellingShingle | Article Davidson, Lisa E Fiorino, Anne-Maria Snydman, David R Hibberd, Patricia L Lactobacillus GG as an Immune Adjuvant for Live Attenuated Influenza Vaccine in Healthy Adults: A Randomized Double Blind Placebo Controlled Trial |
title | Lactobacillus GG as an Immune Adjuvant for Live Attenuated Influenza Vaccine in Healthy Adults: A Randomized Double Blind Placebo Controlled Trial |
title_full | Lactobacillus GG as an Immune Adjuvant for Live Attenuated Influenza Vaccine in Healthy Adults: A Randomized Double Blind Placebo Controlled Trial |
title_fullStr | Lactobacillus GG as an Immune Adjuvant for Live Attenuated Influenza Vaccine in Healthy Adults: A Randomized Double Blind Placebo Controlled Trial |
title_full_unstemmed | Lactobacillus GG as an Immune Adjuvant for Live Attenuated Influenza Vaccine in Healthy Adults: A Randomized Double Blind Placebo Controlled Trial |
title_short | Lactobacillus GG as an Immune Adjuvant for Live Attenuated Influenza Vaccine in Healthy Adults: A Randomized Double Blind Placebo Controlled Trial |
title_sort | lactobacillus gg as an immune adjuvant for live attenuated influenza vaccine in healthy adults: a randomized double blind placebo controlled trial |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071884/ https://www.ncbi.nlm.nih.gov/pubmed/21285968 http://dx.doi.org/10.1038/ejcn.2010.289 |
work_keys_str_mv | AT davidsonlisae lactobacillusggasanimmuneadjuvantforliveattenuatedinfluenzavaccineinhealthyadultsarandomizeddoubleblindplacebocontrolledtrial AT fiorinoannemaria lactobacillusggasanimmuneadjuvantforliveattenuatedinfluenzavaccineinhealthyadultsarandomizeddoubleblindplacebocontrolledtrial AT snydmandavidr lactobacillusggasanimmuneadjuvantforliveattenuatedinfluenzavaccineinhealthyadultsarandomizeddoubleblindplacebocontrolledtrial AT hibberdpatricial lactobacillusggasanimmuneadjuvantforliveattenuatedinfluenzavaccineinhealthyadultsarandomizeddoubleblindplacebocontrolledtrial |